November 27, 2014
Janssen Pharmaceutical K.K. said on November 26 that it filed a new drug application (NDA) in Japan for its anticancer agent ibrutinib on November 25. The drug will be indicated for relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)...read more